Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7882-7905

  Quattropani, Anna ^a   Dorbais, Jérôme ^a   Covini, David ^a   Pittet, Pierre André ^a   Colovray, Véronique ^a   Thomas, Russell J ^c,e   Coxhead, Richard ^c   Halazy, Serge ^a   Scheer, Alexander ^a   Missotten, Marc ^a   Ayala, Guidon ^a   Bradshaw, Charles ^a   De Raemy Schenk, Anne Marie ^a   Nichols, Anthony ^a   Cirillo, Rocco ^b   Tos, Enrico Gillio ^b   Giachetti, Claudio ^b   Golzio, Lucia ^b   Marinelli, Paolo ^b,f   Church, Dennis J ^a   Barberis, Claude ^d   Chollet, André ^a   Schwarz, Matthias K ^a   more..

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

^c EVOTEC UK LTD   (United Kingdom)

^d INSERM   (France)

^e Siena Biotech SpA   (Italy)

^f RCC Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN ANTAGONIST; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PREGNANCY; PREMATURE LABOR; RAT; STRUCTURE ACTIVITY RELATION; UTERUS CONTRACTION;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CRICETULUS; FEMALE; HUMANS; HYDRAZINES; OBSTETRIC LABOR, PREMATURE; PREGNANCY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; UTERINE CONTRACTION;

EID: 28144464067     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050645f     Document Type: Article

References (41)

1. Canadian Preterm Labour Investigators Group. The treatment of preterm labour with beta-adrenergic agonist ritodrine. New Engl. J. Med., 1992, 327, 308-312.
2. Merkatz, I. R.; Peter, J. B.; Barden, T. P. Ritodrine hydrochloride: a betamimetic agent for use in preterm labour. Evidence of efficacy. Obstet. Gynecol. 1980, 56, 7-12.
3. Spellacy, W. N.; Cruz, A. C.; Birk, S. A. Treatment of premature labour with ritodrine: a randomised controlled study. Obstet. Gynecol. 1979, 54, 220-223.
4. Higby, K.; Xenakis, E. M.; Pauerstein, C. J. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am. J. Obstet. Gynecol. 1993, 168, 1247-1256.
5. Macones, G. A. Efficacy of oral beta-agonist maintenance therapy in preterm labor: a meta-analysis. Obstet. Gynecol. 1995, 85, 313-317
6. Beall, M. H.; Edgar, B. W.; Paul, R. H.; Smith-Wallace, T. A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor, Am. J. Obstet. Gynecol. 1985, 153, 854-859.
7. Gabriel, R.; Harika, G.; Saniez, D. Prolonged intravenous ritodrine therapy, a comparison between multiple and singleton pregnancies. Eur. J. Obstet. Gynecol. Reprod. Biol. 1994, 57, 65-71.
8. Young III, W. S.; Shepard, E.; Amico, J.; Hennighausen, L.; Wagner, K.-U.; LaMarca, M. E.; McKinney, C.; Ginns, E. I. Deficiency in mouse oxytocin prevents milk ejection, but not fertility or parturition. J. Neuroendocrinol. 1996, 8, 847-853.
9. Nishimori, K.; Young, L. J.; Guo, Q.; Wang, Z.; Insel, T. R.; Matzuk, M. M. Oxytocin is required for nursing, but is not essential for parturition and reproductive behaviour. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11699-11704.
10. Melin, P.; Trojnar, J.; Johansson, B.; Vilhardt, H.; Aakerlund, M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. 1986, 111, 125-131.
11. Hahn, D. W.; Demarest, K. T.; Ericson, E.; Komm, R. E.; Capetola, R. J.; McGuire, J. L. Evaluation of 1-deamino-[D-Tyr-(O-ethyl)2, Thr4, Orn8]-vasotocin, an oxytocin antagonist, in animal models of uterine contractility and preterm labour: a new tocolytic agent. Am. J. Obstet. Gynecol. 1987, 157, 977-982.
12. Demarest, K. T.; Hahn, D. W.; Ericson, E.; Capetola, R. J.; Fuchs, A. R.; McGuire, J. L. Profile of an oxytocin antagonist, RWJ 22164 for treatment of preterm labour in laboratory models of uterine contractility. Am. J. Perinatol. 1989, 6, 200-204.
13. Romero, R.; Sibai, B. M.; Sanchez-Ramos, L.; Valenzuela, G. J.; Veille, J.-C.; Tabor, B.; Perry, K. G.; Varner, M.; Goodwin, T. M.; Lane, R.; Smith, J.; Shangold, G.; Creasy G. W. An oxytocin receptor antagonist (atosiban) in preterm labour: A randomised, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obst. Gynecol. 2000, 182, 1173-1183.
14. Valenzuela, G. J.; Sanchez-Ramos, L.; Romero, R.; Silver, H. M.; Koltun, W. D.; Millar, L.; Hobbins, J.; Rayburn, W.; Shangold, G.; Wang, J.; Smith, J.; Creasy, G. W. Maintenance treatment of preterm labour with the oxytocin antagonist atosiban. Am. J. Obst. Gynecol. 2000, 182, 1184-1190.
15. Lundin, S.; Breeders, A.; Melin, P. Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin. Endocrinol. 1993, 39, 369-374.
16. Schwarz, M. K.; Page, P. Preterm labor: An overview of current and emerging therapeutics. Curr. Med. Chem. 2003, 10, 1441-1468.
17. Williams, P. D.; Anderson, P. S.; Ball, R. G.; Bock, M. G.; Carroll, L. A.; Chiu, S.-H. L.; Clineschmidt, B. V.; Culberson, J. C.; Erb, J. M. 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)-butyramido)bicyclo[2.2.1] heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): An Orally Bioavailable, Nonpeptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor. J. Med. Chem. 1994, 37, 565-571.
18. Pettibone, D. J.; Clineschmidt, B. V.; Guidotti, M. T.; Lis, E. V.; Reiss, D. R.; Woyden, C. J.; Bock, M. G.; Evans, B. E.; Freidinger, R. M. L-368,899, a potent orally active oxytocin antagonist for potential use in preterm labour. Drug Dev. Res. 1993, 30, 129-142.
19. Thompson, K. L.; Vincent, S. H.; Miller, R. R.; Colletti, A. E.; Alvaro, R. F.; Wallace, M. A.; Feeney, W. P.; Chiu, S. H. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Drug Metab. Dispos. 1997, 25, 1113-1118.
20. Bell, I. M.; Erb, J. M.; Freidinger, R. M.; Gallicchio, S. N.; Guare, J. P.; Guidotti, M. T.; Halpin, R. A.; Hobbs, D. W.; Homnick, C. F.; Kuo, M. S.; Lis, E. V.; Mathre, D. J.; Michelson, S. R.; Pawluczyk, J. M.; Pettibone, D. J.; Reiss, D. R.; Vickers, S.; Williams, P. D.; Woyden, C. J. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3- ylmethyl)piperidin-4-yloxy]-2-methoxybenzoyl]piperidin- 4-yl)-1,4-dihydrobenz[d] [1,3]oxazin-2-one(L-372,662) and related pyridines. J. Med. Chem. 1998, 41, 2146-2163.
21. Williams, P. D.; Bock, M. G.; Evans, B. E.; Freidinger, R. M.; Pettibone, D. J. Progress in the development of oxytocin antagonists for use in preterm labour. Adv. Exp. Med. Biol. 1998, 449, 473-479.
22. Merlot, C.; Domine, D.; Church D. J. Fragment analysis in small molecule discovery. Curr. Opin. Drug Discovery Dev. 2002, 5, 391-399.
23. Merlot, C.; Domine, D.; Cleva, C.; Church D. J. Chemical Substructures in Drug Discovery. Drug Discovery Today 2003, 8, 594-602.
24. Sauer, W. H. B.; Schwarz, M. K. Size does not matter: Scaffold diversity, shape diversity and biological activity of combinatorial libraries. Chimia 2003, 57, 276-283.
25. Sauer, W. H. B.; Schwarz, M. K. Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity. J. Chem. Inf. Comput. Sci. 2003, 43, 987-1003.
26. Gal-Le-Serradeil, C.; Wagnon, J.; Garcia, C.; Lacour, C.; Guiraudou, P.; Christophe, B.; Villanova, G.; Nisato, D.; Maffrand, J. P. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 1993, 92, 224-231.
27. Gal-Le-Serradeil, C.; Valette, G.; Foulon, L.; Germain, G.; Advenier, C.; Naline, E.; Bardou, M.; Martinolle, J. P.; Pouzet, B.; Raufaste, D.; Garcia, C.; Double-Cazanave, E.; Pauly, M.; Pascal, M.; Barbier, A.; Scatton, B.; Maffrand, J. P.; Le Fur, G. SSR126768A(4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4- dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3- pyridylmethyl)-benzamide, hyrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J. Pharm. Exp. Ther. 2004, 309, 414-424.
28. Souers, A. J.; Schürer, S.; Kwack, H.; Virgilio, A. A.; Ellman, J. A. Preparation of enantio-enriched α-bromo acids incorporating diverse functionality. Synthesis 1999, 583-585.
29. Schmid, C. R.; Sluka, J. P.; Duke, K. M. Nucleophilic aromatic substitution on 3-aroyl-2-arylbenzothiophenes. Rapid access to raloxifene and other selective estrogen receptor modulators. Tetrahedron Lett. 1999, 40, 675-678.
30. Beller, M. Breindl, C.; Riermeier, T. H.; Tillack, A. Synthesis of 2,3-dihydroindoles, indoles, and anilines by transition metal-free amination of aryl chlorides J. Org. Chem. 2001, 66, 1403-1412.
31. Zuckermann, R. N.; Kerr, J. M.; Kent, S. B. H.; Moos, W. H. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J. Am. Chem. Soc. 1992, 114, 10646-10647.
32. Tumelty, D.; Schwarz, M. K.; Needels, M. C. Solid-phase synthesis of substituted 1-phenyl-2-aminomethyl-benzimidazoles and 1-phenyl-2-thiomethyl- benzimidazoles. Tetrahedron Lett. 1998, 39, 7467-7470.
33. Schwarz, M. K.; Wells, T. N. C. New therapeutics that modulate chemokine networks. Nat. Rev. Drug Discovery 2002, 1, 347-358.
34. Clineschmidt, B. V.; Pettibone, D. J.; Reiss, D. R.; Lis, E. V.; Haluska, G. J.; Novy, M. J.; Cook, M. J.; Cukierski, M. A.; Kaufman, M. J.; Bock, M. G.; Freidinger, R. M.; Veber, D. F.; Williams, P. D. Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948. J. Pharm. Exp. Ther. 1991, 256, 827-832.
35. Cirillo, R.; Tos, E. G.; Schwarz, M. K.; Quattropani, A.; Scheer, A.; Missotten, M.; Dorbais, J.; Nichols, A.; Borrelli, F.; Giachetti, C.; Golzio, L.; Marinelli, P.; Thomas, R. J.; Chevillard, C.; Laurent, F.; Portet, K.; Barberis, C.; Chollet, A. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2- phenylethyl]-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl) carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J. Pharmacol. Exp. Ther. 2003, 306, 253-261.
36. 1H Dynamic Nuclear Magnetic resonance and Solvent effects in Aryl- and 2-Furylaldehyde Ethylaminoacetylhydrazones. Org. Magn. Reson. 1982, 20, 26-30.
37. Preparation described in: Rivalle, C.; Bisagni, E. Ethyl [4-(acylamino)pyridin-3-yl]glyoxylate and 5-azaisatin as new synthons for a route to various new polyheterocycles. J. Heterocycl. Chem. 1997, 34, 441-444.
38. Bu, X.; Deady, L. W. A preparation of methyl 2-amino-3-formylbenzoate and its use in the Friedlander synthesis. Synth. Commun. 1999, 29, 4223-4233.
39. Wolfbeis, O. S.; Trummer, I.; Knierzinger, A. Syntheses of fluorescent dyes. 10.2-Substitutedpyrano[2,3-c]isoquinoline-3,6-diones and merocyanine dyes from homophthalimides. Liebigs Ann. Chem. 1981, 811-818.
40. Yoshifuji, S.; Arakawa, Y. Ruthenium tetroxide oxidation of 3,4-dihydroisoquinolin-1(2H)-ones: an efficient synthesis of isoquinoline-1, 3,4(2H)-triones. Chem. Pharm. Bull. 1989, 37, 3380-3381.
41. Prepared from 3-aminopropanol: Grillot, A. L.; Hart, D. J. Guanidinium carboxylates: preparation of 3-carboxyoctahydro-9aH-pyrimidin-9a-ylium chloride. Heterocydes 1994, 39, 435-438.